Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077792 · ClinicalTrials.gov registry record · Phase 3
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 20,506
- Enrollment target
NCT00077792: Completed Phase 3 study, sponsored by Sanofi.
NCT00077792 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 20,506 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2560% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077792, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20,506 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after randomization in patients with acute ST-segment elevation myocardial infarction who are eligible to receive fibrinolytic therapy
Interventions
- DRUG Enoxaparin sodium (XRP4563)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,506 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
What the finished NCT00077792 record still lists
NCT00077792 is an interventional study that assigns participants to a tested intervention. Its 20,506 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2560% higher).
The record links to 0 conditions, and to 1 intervention - of which Enoxaparin sodium (XRP4563) is the first listed.
NCT00077792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00077792 about?
NCT00077792 is a clinical study titled "Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)". The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after randomization in patients with acute ST-segment elevation myocardial infarcti...
What is the current status of trial NCT00077792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20,506 participants. The study started on 2002-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00077792?
The interventions under investigation include: Enoxaparin sodium (XRP4563) (DRUG).
Who is sponsoring clinical trial NCT00077792?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00077792's enrollment target sits among peer trials
20,506 9th of 2000 higher than 1,992 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062342 · 20,400 participants · NA
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
- NCT07213531 · 21,000 participants
Enhanced Valves Interventions and Safe AI Generated End Results
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia